Phapros records 511 per cent profit growth to Rp14.97 billion in first half
Jakarta (ANTARA) - The state-owned pharmaceutical company PT Phapros Tbk (PEHA) has booked a net profit growth of 511.01 per cent year-on-year (yoy) to Rp14.97 billion in the first half of 2026, compared to Rp2.45 billion in the same period the previous year.
PEHA President Director Intan Abdams Katoppo, in an official statement in Jakarta on Monday, explained that the company’s performance growth was supported by an increase in sales, improved gross profit margins due to product portfolio enhancements, and operational efficiencies in the factory production process.
“This excellent performance was achieved through implemented strategies, namely maintaining healthy and sustainable financial strength such as more measurable cost control, strategies to increase customer satisfaction, strengthening the portfolio, transforming business systems and processes, as well as optimising human resources and corporate culture,” said Intan.
She continued that the company has successfully maintained its financial performance growth trend and remains optimistic that profit performance will continue to grow by more than two digits until the end of 2026.
“To that end, we are consistently implementing company strategies to continue strengthening innovation and profitability, so that we can provide added value for shareholders and the health of the Indonesian people,” said Intan.
The company’s net profit growth was supported by a 5.37 per cent (yoy) increase in sales to Rp482.85 billion in the first half of 2026, compared to Rp458.22 billion in the same period the previous year.
Additionally, the company was able to achieve efficiencies by reducing the cost of goods sold (COGS) from January to June 2026.
The COGS-to-sales ratio was only 49 per cent in June 2026, whereas in the same period the previous year, it reached 52 per cent (a cost ratio efficiency of 3 per cent).
“This shows that the 5.37 per cent (yoy) increase in sales was higher than the increase in COGS, resulting in the gross profit margin rising to 50.4 per cent compared to 48.0 per cent in the first half of 2025,” said Intan.
Furthermore, the company recorded cash and cash equivalents of Rp162.47 billion as of 30 June 2026, representing a 215.6 per cent (yoy) growth compared to Rp51.49 billion as of 30 June 20t5.
As of 30 June 2026, the company recorded total assets growing by 4.66 per cent (yoy) to Rp1.45 trillion, compared to Rp1.39 trillion as of 31 December 2025.
Currently, the company is preparing the production of a new innovative product in powder form from the non-steroidal anti-inflammatory drug (NSAID) therapeutic class, specifically aimed at helping to manage pain and inflammation in dental cases. This is intended to strengthen the existing and robust dental product line, such as the Pehacaine anaesthetic product.
“This product is currently in the production preparation stage and will soon enter the commercialisation stage, with a target release in the fourth quarter of 2026,” said Intan.
In addition to the domestic business, the company has initiated export business since 2014 and is currently exporting to several countries, including Cambodia, the Philippines, Myanmar, Nigeria, Peru, and Papua New Guinea.
Key export products that have been running for over a decade include analgesics, anti-TB products, multivitamins, anti-motion sickness products, and antibiotics.
In the third and fourth quarters of 2026, the company plans to conduct product shipments to several countries, including the Philippines, Timor-Leste, and Cambodia, with an export sales target of Rp5 billion.
“Moving forward, the company continues to target double-digit growth in export sales to support the domestic business, including increasing the number of potential buyers and expanding product lines,” said Intan.